|  |
| --- |
| Supplementary Table: All meta-analysis |
| Outcomes | No.of Studies | No.of Participants(T/C) | Analysis Results (95%CI),Overall effect P value | HeterogeneityP value, I2(%) | Analytical model |
| Bone mineral density | 13 | 484/470 | MD=0.24 (0.13~0.35), P＜0.00001 | P＜0.00001,I2=91 | random-effect |
| Kupperman scales | 5 | 1132/1107 | MD=-2.35 (-2.76~-1.94),P＜0.00001 | P＜0.00001,I2=83 | random-effect |
| FACT-B | 2 | 315/320 | MD=0.73 (0.11~1.35), P=0.02 | P=0.72,I2=0 | fixed-effect |
|  | 4 | 462/447 | MD=3.01 (1.00~5.02), P=0.003 | P＜0.00001,I2=97 | random-effect |
| VAS Scales | 3 | 90/90 | MD=-2.35 (-3.40~-1.30),P<0.001 | P=0.005,I2=81 | random-effect |
| Efficacy of TCM symptoms | 3 | 78/77 | RR=2.10 (0.90~4.86),P=0.08 | P=0.004,I2=82 | random-effect |
|  | 8 | 245/241 | RR=1.60 (1.40~1.84),P<0.0001 | P=0.89,I2=0 | fixed-effect |
| CD3 | 2 | 94/90 | MD=4.73 (-2.71~12.17),P=0.21 | P＜0.00001,I2=96 | random-effect |
| CD4 | 3 | 220/216 | MD=0.12(-2.66~2.90), P=0.93 | P＜0.00001,I2=95 | random-effect |
| CD8 | 3 | 220/216 | MD=-4.58 (-11.75~2.60),P=0.21 | P＜0.00001,I2=99 | random-effect |
| Serum calcium concentration | 4 | 116/116 | MD=0.02 (-0.02~0.05),P=0.40 | P=0.28,I2=22 | fixed-effect |
| TCM syndrome score | 2 | 42/38 | MD=-9.92 (-25.93~-6.08),P=0.22 | P＜0.00001,I2=98 | random-effect |
|  | 10 | 291/291 | MD=-5.39 (-8.81~-1.97),P=0.002 | P＜0.00001,I2=98 | random-effec |
| ALP | 7 | 201/199 | MD=-0.88 (-8.11~6.35),P=0.81 | P=0.81,I2=98 | random-effect |
| KPS | 5 | 108/108 | MD=3.76 (1.64~5.88),P=0.0005 | P=0.18,I2=38 | fixed-effect |
| Estradiol | 6 | 172/170 | MD=0.14 (-0.57~0.85),P=0.70 | P=0.58,I2=0 | fixed-effect |
| Safety assessment | 3 | 258/225 | MD=-0.21(-0.54~0.13), P=0.28 | P=0.79,I2=0 | fixed-effect |